Elan said today it has started third phaseclinical trials with drug company Biogen on its Multiple Sclerosis drug Antegren.
In the first trial the companies are conducting tests on approximately 900 patients, designed to determine whether Antegren is effective in slowing the rate of disability in MS and reducing the rate of clinical relapses.
The second trial, known as Sentinel is a two year study of approximately 1,200 patients designed to determine whether the treatment of MS with Antegren in combination with Avonex is more effective than Avonex treatment alone in slowing the rate of disability in MS and in reducing the rate of clinical relapses.
Sentinel is the largest ever clinical trial conducted into MS.